Cancer Stem Cell News Volume 10.16 | Apr 28 2021







2021-04-28 | CSCN 10.16


Cancer Stem Cell News by STEMCELL Technologies
Vol. 10.16 – 28 April, 2021
TOP STORY

iPSC Modeling of Stage-Specific Leukemogenesis Reveals BAALC as a Key Oncogene in Severe Congenital Neutropenia

Researchers established a model of stepwise leukemogenesis in congenital neutropenia (CN)/acute myeloid leukemia using CRISPR-Cas9 gene editing of CN patient-derived iPSCs.
[Cell Stem Cell]

AbstractGraphical Abstract
Microscopy images of pluripotent stem cells (PSCs) and PSC-derived cells for the #StemCellfie contest.
PUBLICATIONSRanked by the impact factor of the journal

Targeting the Metabolic Vulnerability of Acute Myeloid Leukemia Blasts with a Combination of Venetoclax and 8-Chloro-Adenosine

Using acute myleoid leukemia cell lines (AML) and leukemia stem cell-enriched blast cells from pre-treatment AML patients, investigators evaluated the effects of 8-chloro-adenosine (8-Cl-Ado), venetoclax and the 8-Cl-Ado/VEN combination on fatty acid metabolism, glycolysis and oxidative phosphorylation using liquid scintillation counting, a Seahorse XF Analyzer and gene set enrichment analysis.
[Journal of Hematology & Oncology]

Full Article

EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma

Scientists established two sorafenib-resistant, patient-derived tumor xenografts that mimicked development of acquired resistance to sorafenib in hepatocellular carcinoma patients.
[Cancer Research]

Abstract

Inhibition of Mitochondrial Translation Suppresses Glioblastoma Stem Cell Growth

Researchers explored the therapeutic potential of targeting mitochondrial translation and report the results of high-content screening with putative blockers of mitochondrial ribosomes.
[Cell Reports]

Full ArticleGraphical Abstract

Glutamine Deficiency Promotes Stemness and Chemoresistance in Tumor Cells through DRP1-Induced Mitochondrial Fragmentation

Investigators showed that glutamine is dispensable for the survival of ovarian and colon cancer cells while it is required for their proliferation.
[Cellular and Molecular Life Sciences]

Abstract

NKX6-1 Mediates Cancer Stem-Like Properties and Regulates Sonic Hedgehog Signaling in Leiomyosarcoma

NKX6-1 enhanced in vitro tumor cell aggressiveness via upregulation of cell proliferation and anchorage-independent growth and promoted in vivo tumor growth.
[Journal of Biomedical Science]

Full Article

Monitoring Levels of Vimentin-Positive Circulating Cancer Stem Cells and Tumor Cells in Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

The cell surface vimentin antibody was used for circulating tumor cells detection and CD133 antibody for circulating CSC detection.
[Lung Cancer]

Abstract

Schisandrin B Inhibits Epithelial-Mesenchymal Transition and Stemness of Large-Cell Lung Cancer Cells and Tumorigenesis in Xenografts via Inhibiting the NF-κB and p38 MAPK Signaling Pathways

Investigators established cancer stem‑like cells derived from large‑cell lung cancer cells, NCI‑H460 and H661, and revealed that Schisandrin B inhibited the viability of cancer stem‑like cells at concentrations of ≥40 µmol/l.
[Oncology Reports]

Abstract

Nano-Realgar Suppresses Lung Cancer Stem Cell Growth by Repressing Metabolic Reprogramming

Isolation and characterization of lung CSCs was performed by magnetic cell sorting and immunocytochemistry, respectively.
[Gene]

Abstract
The StemSpan™ T Cell Generation Kit is designed to promote differentiation of HSPCs into T cells in stroma- and serum-free culture conditions.
REVIEWS

A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy

The authors report on various studies in this field which focus on transformative properties of CSCs and their influence on surrounding cells or targets through the release of cellular cargo in the form of extracellular vesicles.
[Oncotargets and Therapy]

Full Article
INDUSTRY AND POLICY NEWS

D&D Pharmatech Announces Sponsored Research Agreement with Yale University to Optimize Novel Strategies for the Treatment of Brain Cancer and Other Diseases of the Central Nervous System

D&D Pharmatech, Inc. announced it has entered into a sponsored research agreement with Yale University relating to optimization of two novel approaches that allow immune system cells and drug molecules to bypass the blood-brain barrier for the treatment of brain cancer and other disorders.
[D&D Pharmatech, Inc. (Business Wire, Inc.))]

Press Release

Shorla Pharma Announces FDA Filing Acceptance and Priority Review for T-Cell Leukemia Treatment

Shorla Pharma Limited announced that it has submitted, and the FDA has accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia.
[Shorla Pharma Limited (BusinessWire, Inc.)]

Press Release
FEATURED EVENT

Oncolytic Viruses

May 25, 2021
Virtual

> See All Events

JOB OPPORTUNITIES

Head of Department – Gastrointestinal Cancer

Indiana University School of Medicine – Indianapolis, Indiana, United States

Postdoctoral Training Fellow – Pancreatic Cancer

Francis Crick Institute – London, England, United Kingdom

Project Associate – Prostate Cancer Clinical Trials Consortium

Memorial Sloan Kettering – New York, New York, United States

Director – Oncology, Diabetes

Baylor Research Institute – Dallas, Texas, United States

Postdoctoral Research Scientist Positions – Gastrointestinal Oncology

Columbia University Medical Center – New York, New York, United States

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Cancer Stem Cell News Twitter


0
Share